{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:43:33Z","timestamp":1785815013913,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"DOI":"10.7759\/cureus.68560","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:03:20Z","timestamp":1725393800000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Hala A","family":"Abdelhady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adoum","family":"Oumar Abakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra Reddy","family":"Gangavarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed A","family":"Mahmud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anura","family":"Manandhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer","family":"Sabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iana","family":"Malasevskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13407","article-title":"The interplay between sugar and yeast infections: do diabetics have a greater predisposition to develop oral and vulvovaginal candidiasis?","volume":"13","author":"Mohammed L","year":"2021","unstructured":"Mohammed L, Jha G, Malasevskaia I, Goud HK, Hassan A. The interplay between sugar and yeast infections: do diabetics have a greater predisposition to develop oral and vulvovaginal candidiasis?. Cureus. 2021, 13:e13407. 10.7759\/cureus.13407","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46243","article-title":"Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management","volume":"30","author":"Fatima A","year":"2023","unstructured":"Fatima A, Rasool S, Devi S, et al.. Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management. Cureus. 2023, 30:46243. 10.7759\/cureus.46243","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay SM","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al.. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019, 140:e294-324. 10.1161\/CIR.0000000000000691","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13627","article-title":"Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study","volume":"21","author":"Norhammar A","year":"2019","unstructured":"Norhammar A, Bodeg\u00e5rd J, Nystr\u00f6m T, Thuresson M, Nathanson D, Eriksson JW. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes Obes Metab. 2019, 21:1136-45. 10.1111\/dom.13627","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker TH","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E, et al.. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024, 22:378-88. 10.11124\/JBIES-23-00268","journal-title":"JBI Evid Synth"},{"key":"ref8","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2020). Accessed: June 6, 2024: https:\/\/www.researchgate.net\/publication\/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Ra...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12707","article-title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)","volume":"7","author":"Tanaka A","year":"2020","unstructured":"Tanaka A, Hisauchi I, Taguchi I, et al.. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC Heart Fail. 2020, 7:1585-94. 10.1002\/ehf2.12707","journal-title":"ESC Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients: a randomized controlled trial","volume":"84","author":"Kayano H","year":"2020","unstructured":"Kayano H, Koba S, Hirano T, et al.. Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients: a randomized controlled trial. Circ J. 2020, 84:1807-17. 10.1253\/circj.CJ-20-0341","journal-title":"Circ J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2560","article-title":"Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial","volume":"24","author":"Palau P","year":"2022","unstructured":"Palau P, Amiguet M, Dom\u00ednguez E, et al.. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial. Eur J Heart Fail. 2022, 24:1816-26. 10.1002\/ejhf.2560","journal-title":"Eur J Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME Trial","volume":"105","author":"Inzucchi SE","year":"2020","unstructured":"Inzucchi SE, Khunti K, Fitchett DH, et al.. Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab. 2020, 105:3025-35. 10.1210\/clinem\/dgaa321","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007879","article-title":"Patient characteristics, clinical outcomes, and effect of dapagliflozin in relation to duration of heart failure: is it ever too late to start a new therapy?","volume":"13","author":"Yeoh SE","year":"2020","unstructured":"Yeoh SE, Dewan P, Jhund PS, et al.. Patient characteristics, clinical outcomes, and effect of dapagliflozin in relation to duration of heart failure: is it ever too late to start a new therapy?. Circ Heart Fail. 2020, 13:e007879. 10.1161\/CIRCHEARTFAILURE.120.007879","journal-title":"Circ Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial","volume":"43","author":"Singh JS","year":"2020","unstructured":"Singh JS, Mordi IR, Vickneson K, et al.. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial. Diabetes Care. 2020, 43:1356-9. 10.2337\/dc19-2187","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(23)00032-6","article-title":"Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial","volume":"4","author":"Pratley RE","year":"2023","unstructured":"Pratley RE, Cannon CP, Cherney DZ, et al.. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev. 2023, 4:143-54. 10.1016\/S2666-7568(23)00032-6","journal-title":"Lancet Healthy Longev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin M","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, et al.. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020, 142:1028-39. 10.1161\/CIRCULATIONAHA.120.045691","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.03.009","article-title":"Effects of dapagliflozin according to the Heart\u00a0Failure Collaboratory Medical Therapy Score: insights from DAPA-HF","volume":"10","author":"Butt JH","year":"2022","unstructured":"Butt JH, Dewan P, DeFilippis EM, et al.. Effects of dapagliflozin according to the Heart\u00a0Failure Collaboratory Medical Therapy Score: insights from DAPA-HF. JACC Heart Fail. 2022, 10:543-55. 10.1016\/j.jchf.2022.03.009","journal-title":"JACC Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF","volume":"11","author":"Pitt B","year":"2023","unstructured":"Pitt B, Bhatt DL, Szarek M, et al.. Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF. JACC Heart Fail. 2023, 11:879-89. 10.1016\/j.jchf.2023.05.026","journal-title":"JACC Heart Fail"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus","volume":"140","author":"Berg DD","year":"2019","unstructured":"Berg DD, Wiviott SD, Scirica BM, et al.. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation. 2019, 140:1569-77. 10.1161\/CIRCULATIONAHA.119.042685","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato ET","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, et al.. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019, 139:2528-36. 10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado RH","year":"2019","unstructured":"Furtado RH, Bonaca MP, Raz I, et al.. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019, 139:2516-27. 10.1161\/CIRCULATIONAHA.119.039996","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial","volume":"143","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced Trial. Circulation. 2021, 143:337-49. 10.1161\/CIRCULATIONAHA.120.051824","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee MM","year":"2021","unstructured":"Lee MM, Brooksbank KJ, Wetherall K, et al.. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021, 143:516-25. 10.1161\/CIRCULATIONAHA.120.052186","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108588","article-title":"Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes","volume":"37","author":"Kr\u00e4mer BK","year":"2023","unstructured":"Kr\u00e4mer BK, Hauske SJ, Chilton R, et al.. Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes. J Diabetes Complications. 2023, 37:108588. 10.1016\/j.jdiacomp.2023.108588","journal-title":"J Diabetes Complications"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021661","article-title":"Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the CANVAS Trial","volume":"10","author":"Sen T","year":"2021","unstructured":"Sen T, Li J, Neuen BL, et al.. Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the CANVAS Trial. J Am Heart Assoc. 2021, 10:e021661. 10.1161\/JAHA.121.021661","journal-title":"J Am Heart Assoc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020053","article-title":"Cardio\/kidney composite end points: a post hoc analysis of the EMPA-REG OUTCOME Trial","volume":"10","author":"Ferreira JP","year":"2021","unstructured":"Ferreira JP, Kraus BJ, Zwiener I, et al.. Cardio\/kidney composite end points: a post hoc analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2021, 10:e020053. 10.1161\/JAHA.120.020053","journal-title":"J Am Heart Assoc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt DL","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al.. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021, 384:117-28. 10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial","volume":"140","author":"Nassif ME","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F, et al.. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation. 2019, 140:1463-76. 10.1161\/CIRCULATIONAHA.119.042929","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01323-5","article-title":"Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia","volume":"20","author":"Real J","year":"2021","unstructured":"Real J, Vlacho B, Ortega E, et al.. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol. 2021, 20:139. 10.1186\/s12933-021-01323-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2021.07.005","article-title":"ADDition of DAPAgliflozin, sodium-glucose cotransporter-2 inhibitor to angiotensin receptor blocker-neprilysin inhibitors non-responders in patient with refractory heart failure with reduced ejection fraction (ADD DAPA trial)","volume":"73","author":"Jariwala P","year":"2021","unstructured":"Jariwala P, Jadhav K, Punjani A, Boorugu H, Mari AR. ADDition of DAPAgliflozin, sodium-glucose cotransporter-2 inhibitor to angiotensin receptor blocker-neprilysin inhibitors non-responders in patient with refractory heart failure with reduced ejection fraction (ADD DAPA trial). Indian Heart J. 2021, 73:605-11. 10.1016\/j.ihj.2021.07.005","journal-title":"Indian Heart J"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0877-2","article-title":"Canagliflozin for Japanese patients with chronic heart failure and type II diabetes","volume":"18","author":"Sezai A","year":"2019","unstructured":"Sezai A, Sekino H, Unosawa S, Taoka M, Osaka S, Tanaka M. Canagliflozin for Japanese patients with chronic heart failure and type II diabetes. Cardiovasc Diabetol. 2019, 18:76. 10.1186\/s12933-019-0877-2","journal-title":"Cardiovasc Diabetol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-19-0070","article-title":"Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus","volume":"1","author":"Nakagaito M","year":"2019","unstructured":"Nakagaito M, Joho S, Ushijima R, Nakamura M, Kinugawa K. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circ Rep. 2019, 1:405-13. 10.1253\/circrep.CR-19-0070","journal-title":"Circ Rep"},{"key":"ref35","article-title":"Results of SGLT2 inhibitor treatment in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction","volume":"6","author":"Ozisik H","year":"2021","unstructured":"Ozisik H, Cetinkalp S, Candemir A, et al.. Results of SGLT2 inhibitor treatment in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction. J Integr Cardiol. 2021, 6:1-5.","journal-title":"J Integr Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281110-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-heart-failure-in-patients-with-type-2-diabetes-mellitus-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:03:24Z","timestamp":1725393804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281110-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-heart-failure-in-patients-with-type-2-diabetes-mellitus-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.68560","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,3]]}}}